Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Rev. bras. enferm ; 72(6): 1519-1525, Nov.-Dec. 2019. tab, graf
Artículo en Inglés | LILACS, BDENF | ID: biblio-1042193

RESUMEN

ABSTRACT Objective: To construct and validate an educational technology (ET) on fatigue and non-pharmacological strategies for the management of this symptom in people with cancer undergoing outpatient antineoplastic chemotherapy. Method: This is a methodological study composed of three stages: 1) elaboration of the ET using the theoretical-methodological model of Doak, Doak and Root; 2) validation of content and appearance by seven nurses via the content validity index (CVI); and 3) a pilot test with 10 patients. Results: The ET "Knowing and coping with fatigue" contemplates the definition of fatigue, its causes and the interventions of physical exercise practice, sleep hygiene, energy conservation and behavioral intervention. The overall CVI obtained with the judges was 0.95. Conclusion: The ET presented content and appearance validity for health education regarding fatigue related to antineoplastic chemotherapy in outpatient cancer patients.


RESUMEN Objetivo: Construir y validar una tecnología educativa (TE) sobre fatiga y estrategias no farmacológicas para el manejo del síntoma en personas con cáncer en tratamiento quimioterápico antineoplásico ambulatorio. Método: Estudio metodológico que consta de tres etapas: 1) elaboración de la TE utilizando el modelo teórico-metodológico de Doak, Doak y Root; 2) validación de contenido y apariencia por siete jueces enfermeros, por medio del índice de validez de contenido (IVC); y 3) realización de una prueba piloto con 10 pacientes. Resultados: La TE "Conociendo y lidiando con la fatiga" contempla la definición de fatiga, sus causas y las intervenciones con la práctica de ejercicios físicos, la higiene del sueño, la conservación de energía y la intervención comportamental. El IVC total obtenido con los jueces fue de 0,95. Conclusión: La TE presentó validez de contenido y apariencia para la educación en salud con relación a la fatiga relacionada a la quimioterapia antineoplásica en pacientes oncológicos ambulatorios.


RESUMO Objetivo: Construir e validar tecnologia educativa (TE) sobre fadiga e estratégias não farmacológicas para manejo desse sintoma em pessoas com câncer em tratamento quimioterápico antineoplásico ambulatorial. Método: Estudo metodológico composto por três etapas: 1) elaboração da TE, utilizando o modelo teórico-metodológico de Doak, Doak e Root; 2) validação de conteúdo e aparência por sete juízes enfermeiros, por meio do índice de validade de conteúdo (IVC); e 3) realização de teste piloto com 10 pacientes. Resultados: A TE "Conhecendo e lidando com a fadiga" contempla a definição de fadiga, suas causas e as intervenções de prática de exercícios físicos, higiene do sono, conservação de energia e intervenção comportamental. O IVC global obtido com os juízes foi de 0,95. Conclusão: A TE apresentou validade de conteúdo e aparência para a educação em saúde com relação à fadiga relacionada à quimioterapia antineoplásica em pacientes oncológicos ambulatoriais.


Asunto(s)
Humanos , Adulto , Tecnología Educacional/métodos , Fatiga/inducido químicamente , Fatiga/terapia , Neoplasias/tratamiento farmacológico , Antineoplásicos/efectos adversos , Pacientes Ambulatorios , Proyectos Piloto , Reproducibilidad de los Resultados , Metabolismo Energético , Terapia por Ejercicio , Higiene del Sueño
2.
Rev. gaúch. enferm ; 36(2): 89-96, Apr-Jun/2015. tab
Artículo en Inglés | LILACS, BDENF | ID: lil-752574

RESUMEN

OBJECTIVE: This study aimed to investigate the quality of life of women suffering from breast cancer undergoing chemotherapy in public and private health care systems. METHOD: It is an observational, prospective study with 64 women suffering from breast cancer. Data was collected with two instruments: Quality of Life Questionnaire C30 and Breast Cancer Module BR23. By applying Mann Whitney and Friedman's statistical tests, p values < 0.05 were considered statistically significant. RESULTS: The significant results in public health care systems were: physical functions, pain symptom, body image, systemic effects and outlook for the future. In private health care systems, the results were sexual, social functions and body image. Women's quality of life was harmed by chemotherapy in both institutions. CONCLUSION: The quality of life of women has been harmed as a result of the chemotherapy treatment in both institutions, but in different domains, indicating the type of nursing care that should be provided according to the characteristics of each group. .


OBJETIVO: Se objetivó investigar la calidad de vida de las mujeres con neoplasia mamaria sometidas a quimioterapia, en el seguro médico público y privado. MÉTODO: Se trata de un estudio observacional, de cohorte, prospectivo, realizado con 64 mujeres con neoplasia mamaria. Los datos fueron recolectados mediante dos instrumentos Quality of Life Questionnaire C30 y Breast Cancer Module BR23. Para el análisis los datos se utilizaron pruebas estadísticas de Mann Whitney y Friedman, con valores estadísticamente significativas para p <005. RESULTADOS: Fueron verificadas diferencias estadísticamente significativas en el seguro médico público: la función física, síntoma dolor, la imagen corporal, los efectos sistémicos en las perspectivas de futuro, en el seguro médico privado fueron la función sexual, la imagen social y el cuerpo. CONCLUSIÓN: La calidad de vida de las mujeres se ha visto comprometida como consecuencia de la quimioterapia en ambas instituciones, pero en diferentes dominios que subsidia la atención de enfermería dirigida según las características de cada grupo. .


OBJETIVO: O objetivo deste estudo foi investigar a qualidade de vida das mulheres com neoplasia mamária submetidas à quimioterapia nos convênios público e privado. MÉTODO: Trata-se de estudo observacional, de coorte prospectivo, realizado com 64 mulheres portadoras de neoplasia mamária. Os dados foram coletados com a utilização dos instrumentos Quality of Life Questionnaire C30 e Breast Cancer Module BR23. Para análise dos dados, foram utilizados os testes estatísticos de Mann Whitney e Friedman, com valores estatisticamente significantes para p<005. RESULTADOS: Os resultados significantes no convênio público foram: função física, dor, imagem corporal, efeitos sistêmicos e perspectivas futuras. No convênio privado, foram: função sexual, social e imagem corporal. CONCLUSÃO: A qualidade de vida das mulheres foi comprometida em decorrência do tratamento quimioterápico em ambas as instituições, porém em domínios diferentes, o que subsidia um cuidado de enfermagem direcionado de acordo com as características de cada grupo. .


Asunto(s)
Humanos , Femenino , Adulto , Persona de Mediana Edad , Anciano , Neoplasias de la Mama/psicología , Calidad de Vida , Actividades Cotidianas , Antineoplásicos/efectos adversos , Antineoplásicos/uso terapéutico , Imagen Corporal , Brasil , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/economía , Emociones , Fatiga/inducido químicamente , Fatiga/psicología , Enfermedades Gastrointestinales/inducido químicamente , Enfermedades Gastrointestinales/psicología , Hábitos , Hospitales Privados , Hospitales Públicos , Relaciones Interpersonales , Linfedema/psicología , Ocupaciones , Pronóstico , Estudios Prospectivos , Autoimagen , Conducta Sexual , Encuestas y Cuestionarios
3.
Gut and Liver ; : 696-703, 2013.
Artículo en Inglés | WPRIM | ID: wpr-209556

RESUMEN

BACKGROUND/AIMS: We investigated the effects of sorafenib monotherapy on advanced hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT) in a clinical setting. METHODS: In total, 143 consecutive patients with unresectable HCC were treated with sorafenib. Among these patients, 30 patients with advanced HCC and PVTT (Vp3 or 4) were treated with sorafenib monotherapy. RESULTS: All patients had a performance status of 1 to 2 (Eastern Cooperative Oncology Group 1/2, 20/10) and Child-Pugh class A or B (A/B, 17/13). Eleven patients had modified Union for International Cancer Control stage IVA tumors, whereas 19 had stage IVB tumors. All patients had PVTT (Vp3, 6; Vp4, 24). Following sorafenib monotherapy, three patients (10.0%) had a partial response with PVTT revascularization, and nine (30.0%) had stable disease, with a disease control rate of 33.3%. The median overall survival was 3.1 months (95% confidence interval [CI], 2.70 to 3.50), and the median progression-free survival was 2.0 months (95% CI, 1.96 to 2.05). Fatigue and hand-foot skin reactions were the most troublesome side effects. CONCLUSIONS: A limited proportion of patients with advanced HCC and PVTT exhibited a remarkable outcome after sorafenib monotherapy, although the treatment results in this type of patient is extremely poor. Further studies to predict good responders to personalized therapy are warranted.


Asunto(s)
Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Persona de Mediana Edad , Anorexia/inducido químicamente , Antineoplásicos/efectos adversos , Carcinoma Hepatocelular/tratamiento farmacológico , Diarrea/inducido químicamente , Supervivencia sin Enfermedad , Fatiga/inducido químicamente , Síndrome Mano-Pie/etiología , Estimación de Kaplan-Meier , Neoplasias Hepáticas/tratamiento farmacológico , Imagen por Resonancia Magnética , Náusea/inducido químicamente , Invasividad Neoplásica , Niacinamida/efectos adversos , Compuestos de Fenilurea/efectos adversos , Vena Porta/patología , Modelos de Riesgos Proporcionales , Tomografía Computarizada Espiral , Trombosis de la Vena/tratamiento farmacológico
4.
Journal of Korean Medical Science ; : 52-57, 2006.
Artículo en Inglés | WPRIM | ID: wpr-181118

RESUMEN

The effects of treatment with oral capecitabine vs. bolus 5-FU, administered concurrently with preoperative radiotherapy, were compared in the treatment of locally advanced rectal cancer (LARC). One hundred and twenty-seven patients with LARC received concurrent preoperative chemoradiation using two cycles bolus 5-FU (500 mg/m2/day) plus leucovorin (LV, 20 mg/m2/day) (Group I). Another LARC group received concurrent chemoradiation using two cycles 1,650 mg/m2/day of oral capecitabine and 20 mg/m2/day of LV (Group II, 97 patients). Radiation was delivered to the primary tumor at 50.4 Gy in both groups. Definitive surgery was performed 6 weeks after the completion of chemoradiation. A pathologic complete remission was achieved in 11.4% of patients in Group I and in 22.2% of patients in Group II (p= 0.042). The down-staging rates of the primary tumor and lymph nodes were 39.0/ 68.7% in Group I and 61.1/87.5% in Group II (p=0.002/0.005). Sphincter-preserving surgery was possible in 42.1% of patients in Group I and 66.7% of those in Group II (p=0.021). Grade 3 or 4 leucopenia, diarrhea, and radiation dermatitis were statistically more prevalent in Group I than in Group II, while the opposite was true for grade 3 hand-foot syndrome. Preoperative chemoradiation using oral capecitabine was better tolerated than bolus 5-FU and was more effective in the promotion of both down-staging and sphincter preservation in patients with LARC.


Asunto(s)
Adulto , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Administración Oral , Antimetabolitos Antineoplásicos/administración & dosificación , Terapia Combinada , Estudio Comparativo , Desoxicitidina/administración & dosificación , Diarrea/inducido químicamente , Esquema de Medicación , Fatiga/inducido químicamente , Fluorouracilo/administración & dosificación , Leucopenia/inducido químicamente , Estadificación de Neoplasias , Complicaciones Posoperatorias/terapia , Neoplasias del Recto/tratamiento farmacológico , Estudios Retrospectivos , Resultado del Tratamiento
5.
Journal of Korean Medical Science ; : 618-623, 2005.
Artículo en Inglés | WPRIM | ID: wpr-147616

RESUMEN

Although various combinations of chemotherapy regimens have been tried for patients with esophageal cancer, their duration of survival is extremely poor. In this study, we investigated the safety and clinical efficacy of paclitaxel and cisplatin chemotherapy in metastatic or recurrent esophageal cancer. 32 patients enrolled in this study and the median age was 60 yr. Of all the 32, 28 patients (88%) had been treated previously, 22 of them with chemotherapy or radiation therapy. All patients in the study received biweekly paclitaxel (90 mg/m2) followed by cisplatin (50 mg/m2). One patient (3%) responded completely, and 12 patients (38%) showed a partial response; in 9 patients (28%) the disease remained stable, and in 10 patients (31%) it progressed. The objective response rate was 41%. The median duration of response was 4.8 months, and the median overall survival in all patients was 7 months. The 1-yr and 2-yr survival rates were 28.1% and 7.1%, respectively. Grade 3 or 4 of neutropenia and anemia were observed in 6 (19%) and 5 (16%) patients, respectively. The major non-hematologic toxicity was fatigue, but most of them could manageable. In conclusion, biweekly paclitaxel and cisplatin is effective in patients with metastatic or recurrent esophageal cancer.


Asunto(s)
Anciano , Humanos , Masculino , Persona de Mediana Edad , Anemia/inducido químicamente , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Neoplasias Óseas/tratamiento farmacológico , Cisplatino/administración & dosificación , Diarrea/inducido químicamente , Neoplasias Esofágicas/tratamiento farmacológico , Fatiga/inducido químicamente , Neoplasias Hepáticas/tratamiento farmacológico , Neoplasias Pulmonares/tratamiento farmacológico , Metástasis Linfática , Náusea/inducido químicamente , Recurrencia Local de Neoplasia , Paclitaxel/administración & dosificación , Análisis de Supervivencia , Trombocitopenia/inducido químicamente , Factores de Tiempo , Resultado del Tratamiento , Vómitos/inducido químicamente
6.
Journal of Korean Academy of Nursing ; : 177-185, 2005.
Artículo en Coreano | WPRIM | ID: wpr-80607

RESUMEN

PURPOSE: The purpose of this study was to identify the effects of foot reflexology on nausea, vomiting and fatigue in breast cancer patients undergoing chemotherapy. METHOD: The research was a quasi-experimental study using a non-equivalent pre-post design and was conducted from Jan. 26, to Mar. 20, 2004. The subjects consisted of 34 patients with 18 in the experimental group and 16 in control group. A pretest and 2 posttests were conducted to measure nausea, vomiting and fatigue. For the experimental group, foot reflexology, which was consisted of 4 phases for 40 minutes, was given by a researcher and 4 research assistants. The collected data were analyzed by repeated measures ANOVA using the SPSS WIN 10.0 program. RESULTS: There was a statistically significant decrease in nausea, and vomiting in the experimental group compared to the control group over two different times. In addition, there was a statistically significant decrease in fatigue in the experimental group compared to the control group over two different times. CONCLUSION: Foot reflexology was effective on nausea, vomiting and fatigue in breast cancer patients receiving chemotherapy in this study. Therefore, foot reflexology can be usefully utilized as a nursing intervention in the field of cancer nursing for breast cancer patients receiving chemotherapy.


Asunto(s)
Persona de Mediana Edad , Humanos , Femenino , Adulto , Vómitos/inducido químicamente , Náusea/inducido químicamente , Masaje , Pie , Fatiga/inducido químicamente , Neoplasias de la Mama/tratamiento farmacológico , Antineoplásicos/efectos adversos
7.
J Indian Med Assoc ; 2004 Sep; 102(9): 525-7
Artículo en Inglés | IMSEAR | ID: sea-97051

RESUMEN

The objective of the study was to assess the efficacy, safety and tolerability of a fixed dose combination of telmisartan 40 mg and hydrochlorothiazide 12.5 mg in adult Indian patients with mild to moderate hypertension. A prospective, multicentric, open-label, non-comparative, phase IV study was conducted. A total of 353 patients of either sex, between 18- 65 years of age with supine blood pressure (BP) levels of systolic BP (SBP) of 140-200 mmHg and diastolic BP (DBP) of 95-114 mmHg were included. After a placebo run-in period of 2 weeks, each patient received a fixed dose combination of telmisartan/hydrochlorothiazide (40mg/12.5mg) once daily, for 8 weeks. Supine BP was assessed at the end of every 2 weeks. Tolerability and safety were assessed by physical examination, laboratory parameters and evaluation of adverse events. A total of 339 patients completed the study with 14 drop-out cases because of loss to follow-up. There was a significant fall (p<0.05) in both the SBP and DBP starting from the second week as compared to the baseline. Mean SBP had a significant reduction of 23.55 mmHg (15.0%) and 27.79 mmHg (18%) at the end of 6th and 8th week respectively, compared to baseline values. Mean DBP had also had a significant reduction of 12.51 mmHg (12.6%) and 15.17 mmHg (15.3%) at the end of 6th and 8th week respectively, compared to baseline values. This combination was well tolerated with only 3.9% of the total cases reporting mild adverse events like fatigue, dizziness, nausea, diarrhoea etc. The laboratory values were within normal limits. Fixed dose combination of telmisartan/hydrochlorothiazide (40 mg/12.5 mg) once daily has a significant therapeutic effect and a good tolerability profile in adult Indian patients with mild to moderate hypertension.


Asunto(s)
Adolescente , Adulto , Bloqueadores del Receptor Tipo 1 de Angiotensina II/administración & dosificación , Antihipertensivos/administración & dosificación , Bencimidazoles/administración & dosificación , Benzoatos/administración & dosificación , Mareo/inducido químicamente , Quimioterapia Combinada , Fatiga/inducido químicamente , Femenino , Humanos , Hidroclorotiazida/administración & dosificación , Hipertensión/tratamiento farmacológico , India , Masculino , Persona de Mediana Edad , Náusea/inducido químicamente , Estudios Prospectivos , Resultado del Tratamiento
8.
Indian J Physiol Pharmacol ; 1988 Oct-Dec; 32(4): 293-8
Artículo en Inglés | IMSEAR | ID: sea-106544

RESUMEN

A double blind comparative study was conducted to evaluate the efficacy and safety of penfluridol and trifluoperazine in patients of chronic schizophrenia. Penfluridol was administered once weekly while trifluoperazine was administered twice daily by preparing identical capsules. The data revealed that both the compounds were similarly effective in maintaining control of symptoms of chronic schizophrenia. However, penfluridol has a definite advantage over trifluoperazine since it is administered once a week instead of twice a day.


Asunto(s)
Adulto , Ensayos Clínicos como Asunto , Método Doble Ciego , Esquema de Medicación , Fatiga/inducido químicamente , Femenino , Humanos , Masculino , Penfluridol/administración & dosificación , Piperidinas/uso terapéutico , Distribución Aleatoria , Esquizofrenia/tratamiento farmacológico , Psicología del Esquizofrénico , Trastornos del Inicio y del Mantenimiento del Sueño/inducido químicamente , Trifluoperazina/administración & dosificación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA